Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis

Table 3 Subgroup analyses of the toxicities of COX-2 inhibitor

Toxicity	RCT, n	RR (95%CI)	P value for between groups	Toxicity	RCT, n	RR (95%CI)	P value for between groups
Leucopenia	8	1.20 (1.03, 1.40)	0.020	Diarrhea	3	1.31 (0.64, 2.71)	0.460
COX-2 inhibitor type				COX-2 inhibitor type
Celecoxib	6	1.26 (1.07, 1.49)	0.280	Celecoxib	2	1.24 (0.59, 2.62)	0.940
Rofecoxib	1	0.80 (0.43, 1.50)		Rofecoxib	1	3.05 (0.13, 74.1)
Apricoxib	1	0.92 (0.47, 1.80)		Apricoxib	1	2.69 (0.33, 22.3)
Treatment line				Treatment line
First-line	6	1.20 (1.02, 1.42)	0.900	First-line	2	0.91 (0.40, 2.07)	0.080
Second-line	2	1.19 (0.76, 1.87)		Second-line	2	4.10 (0.95, 17.60)
Phase				Phase
II	4	1.14 (0.77, 1.69)	0.720	II	2	4.10 (0.95, 17.60)	0.080
III	4	1.21 (1.03, 1.44)		III	2	0.91 (0.40, 2.07)
Thrombocytopenia	8	1.33 (1.05, 1.68)	0.017	Gastric ulcer	2	1.00 (0.25, 3.97)	0.997
COX-2 inhibitor type				COX-2 inhibitor type
Celecoxib	6	1.40 (1.08, 1.81)	0.560	Celecoxib	2	1.00 (0.25, 3.97)	NA
Rofecoxib	1	1.02 (0.59, 1.76)		Rofecoxib	NA	NA
Apricoxib	1	3.00 (0.13, 71.30)		Apricoxib	NA	NA
Treatment line				Treatment line
First-line	6	1.24 (0.97, 1.58)	0.090	First-line	2	1.00 (0.25, 3.97)	NA
Second-line	2	2.66 (1.14, 6.17)		Second-line	NA	NA
Phase				Phase
II	4	2.69 (1.19, 6.07)	0.070	II	2	1.00 (0.25, 3.97)	NA
III	4	1.23 (0.96, 1.56)		III	NA	NA
Anemia	5	1.32 (0.75, 2.33)	0.343	Asthenia	7	0.84 (0.56, 1.28)	0.426
COX-2 inhibitor type				COX-2 inhibitor type
Celecoxib	3	2.76 (0.96, 7.97)	0.110	Celecoxib	5	0.94 (0.60, 1.48)	0.590
Rofecoxib	1	0.80 (0.38, 1.69)		Rofecoxib	1	0.51 (0.16, 1.64)
Apricoxib	2	3.14 (0.51, 19.50)		Apricoxib	2	0.94 (0.20, 4.44)
Treatment line				Treatment line
First-line	3	1.07 (0.56, 2.05)	0.140	First-line	5	0.92 (0.60, 1.42)	0.560
Second-line	3	2.91 (0.89, 9.98)		Second-line	3	0.53 (0.15, 1.88)
Phase				Phase
II	4	3.03 (1.00, 9.24)	0.100	II	4	0.75 (0.28, 2.02)	0.900
III	2	1.01 (0.52, 1.97)		III	3	0.86 (0.54, 1.39)
Nausea	7	0.85 (0.53, 1.36)	0.507	Cardiotoxicity	5	2.39 (1.06, 5.42)	0.037
COX-2 inhibitor type				COX-2 inhibitor type
Celecoxib	5	0.87 (0.50, 1.51)	0.960	Celecoxib	3	1.55 (0.53, 4.50)	0.540
Rofecoxib	1	0.76 (0.27, 2.13)		Rofecoxib	1	4.58 (1.01, 20.70)
Apricoxib	2	1.00 (0.15, 6.72)		Apricoxib	1	3.00 (0.13, 71.30)
Treatment line				Treatment line
First-line	6	0.84 (0.52, 1.37)	0.860	First-line	4	2.35 (1.01, 5.49)	0.880
Second-line	2	1.00 (0.15, 6.72)		Second-line	1	3.00 (0.13, 71.30)
Phase				Phase
II	4	1.44 (0.58, 3.59)	0.400	II	1	3.00 (0.13, 71.30)	0.880
III	3	0.67 (0.36, 1.25)		III	4	2.35 (1.01, 5.49)
Neurotoxicity	4	1.02 (0.23, 4.45)	0.977
COX-2 inhibitor type
Celecoxib	3	1.02 (0.18, 5.83)	0.100
Rofecoxib	1	1.02 (0.06, 16.07)
Apricoxib	NA	NA
Treatment line
First-line	4	1.02 (0.23, 4.45)	1.000
Second-line	NA	NA
Phase
II	2	3.09 (0.13, 73.20)	0.420
III	2	0.68 (0.11, 4.04)

RCT: Randomized controlled trial; RR: Relative risk; CI: Confidence interval; NA: Not applicable.